Table 5.

Difference-in-difference-in-difference estimation incorporating individuals who are exempt from co-payments

	T2D-associated pharmaceutical costs
	Year 1	Year 2
	Est. (SE)	Est. (SE)
Variables
$\mathrm{Treat}$ (yes/no)	− 0.062*** (0.011)	− 0.058*** (0.010)
$\mathrm{Post}$ (yes/no)	2.363*** (0.014)	2.115*** (0.021)
$\mathrm{No}\mathrm{copay}$ (yes/no)	0.302*** (0.033)	0.292*** (0.036)
$\mathrm{Treat}\times \mathrm{Post}$	0.058*** (0.018)	− 0.012 (0.036)
$\mathrm{Treat}\times \mathrm{No}\mathrm{copay}$	0.011 (0.047)	0.012 (0.046)
$\mathrm{Post}\times \mathrm{No}\mathrm{copay}$	− 0.165*** (0.049)	− 0.375*** (0.116)
$\mathrm{Treat}\times \mathrm{Post}\times \mathrm{No}\mathrm{copay}$	− 0.027 (0.067)	0.181 (0.154)
Observations	2389

T2D type 2 diabetes mellitus, Est estimate, SE standard error, FDC fixed-dose combination

*p < 0.10, **p < 0.05, ***p < 0.01